Insider · CIK 0001586660

Golumbeski George

Reports to the SEC for 7 companies · NEWTON, MA

sec.gov

Transactions

Companies

Filings

CIK

0001586660

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-03	ABOSAcumen Pharmaceuticals, Inc.A Award	Director	AAward	+35.5K sh	—	—	35,500
2026-06-03	ABOSAcumen Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+53.3K sh	—	—	53,250
2026-05-29	STTKShattuck Labs, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+81K sh	—	—	81,000
2025-12-05	Mural Oncology plcStock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−8,637 sh	—	—	0
2025-12-05	Mural Oncology plcStock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−15.3K sh	—	—	0
2025-11-06	ABOSAcumen Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Director	AAward	+50K sh	—	—	50,000
2025-07-31	Sage Therapeutics, Inc.U Disposition from Tender	Director	UDisposition from Tender	−8,000 sh	—	—	0
2025-07-31	Sage Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−21.5K sh	—	—	0
2025-07-31	Sage Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−13.6K sh	—	—	0
2025-07-14	STTKShattuck Labs, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+33.2K sh	—	—	33,150
2025-06-11	Sage Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+21.5K sh	—	—	21,500
2025-06-11	Mural Oncology plcStock Option (right to buy)A Award	Director	AAward	+8,637 sh	—	—	8,637
2025-01-03	Sage Therapeutics, Inc.Stock Options (Right to buy)A Award	Director	AAward	+13.6K sh	—	—	13,593
2024-07-30	Mural Oncology plcStock Option (right to buy)A Award	Director	AAward	+15.3K sh	—	—	15,334
2024-06-21	STTKShattuck Labs, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+27.7K sh	—	—	27,700
2024-06-10	Sage Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+12.5K sh	—	—	12,500
2024-01-03	Sage Therapeutics, Inc.Stock Options (Right to buy)A Award	Director	AAward	+3,495 sh	—	—	3,495
2023-06-15	Sage Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	—	—	10,000
2023-05-26	STTKShattuck Labs, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+40.3K sh	—	—	40,258
2023-01-04	Sage Therapeutics, Inc.Stock Options (Right to buy)A Award	Director	AAward	+2,108 sh	—	—	2,108
2022-06-16	Sage Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+9,947 sh	—	—	9,947
2022-06-08	STTKShattuck Labs, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+40.3K sh	—	—	40,258
2022-05-05	Sage Therapeutics, Inc.P Purchase	Director	PPurchase	+8,000 sh	$31.45	+$252K	8,000
2022-04-26	STTKShattuck Labs, Inc.P Purchase	Director	PPurchase	+28.3K sh	$3.63	+$103K	54,613
2022-04-22	STTKShattuck Labs, Inc.P Purchase	Director	PPurchase	+234 sh	$3.67	+$858.78	26,283
2022-04-21	STTKShattuck Labs, Inc.P Purchase	Director	PPurchase	+26K sh	$3.69	+$96.1K	26,049
2022-01-04	Sage Therapeutics, Inc.Stock Options (Right to buy)A Award	Director	AAward	+1,638 sh	—	—	1,638
2021-06-19	STTKShattuck Labs, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+3,434 sh	—	—	3,434
2021-06-10	Sage Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	—	—	10,000
2021-01-05	Sage Therapeutics, Inc.Stock Options (Right to buy)A Award	Director	AAward	+832 sh	—	—	832
2020-12-22	STTKShattuck Labs, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+1,286 sh	—	—	1,286
2020-07-06	CRBPCorbus Pharmaceuticals Holdings, Inc. · Stock Option(right to buy)A Award	Director	AAward	+81K sh	—	—	81,000
2020-06-09	Sage Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	—	—	10,000
2020-02-26	ENTAENANTA PHARMACEUTICALS INC · Stock Option (right to buy)A Award	Director	AAward	+10K sh	—	—	10,000
2020-01-03	Sage Therapeutics, Inc.Stock Options (Right to buy)A Award	Director	AAward	+976 sh	—	—	976
2019-06-05	Sage Therapeutics, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+10K sh	—	—	10,000
2019-03-04	ENTAENANTA PHARMACEUTICALS INCM Exercise/Conversion	Director	MExercise/Conversion	+9,280 sh	$36.61	+$340K	9,280
2019-03-04	ENTAENANTA PHARMACEUTICALS INC · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−9,280 sh	—	—	0
2019-03-04	ENTAENANTA PHARMACEUTICALS INCS Sale	Director	SSale	−9,280 sh	$103.65	−$962K	0
2019-02-28	ENTAENANTA PHARMACEUTICALS INC · Stock Option (right to buy)A Award	Director	AAward	+5,000 sh	—	—	5,000
2019-02-12	ENTAENANTA PHARMACEUTICALS INC · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−3,728 sh	—	—	0
2019-02-12	ENTAENANTA PHARMACEUTICALS INC · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−7,500 sh	—	—	0
2019-02-12	ENTAENANTA PHARMACEUTICALS INCS Sale	Director	SSale	−11.2K sh	$90.07	−$1.01M	0
2019-02-12	ENTAENANTA PHARMACEUTICALS INCM Exercise/Conversion	Director	MExercise/Conversion	+7,500 sh	$29.02	+$218K	11,228
2019-02-12	ENTAENANTA PHARMACEUTICALS INCM Exercise/Conversion	Director	MExercise/Conversion	+3,728 sh	$25.58	+$95.4K	3,728
2019-02-11	ENTAENANTA PHARMACEUTICALS INC · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,272 sh	—	—	3,728
2019-02-11	ENTAENANTA PHARMACEUTICALS INCS Sale	Director	SSale	−2,272 sh	$90.03	−$205K	0
2019-02-11	ENTAENANTA PHARMACEUTICALS INCM Exercise/Conversion	Director	MExercise/Conversion	+2,272 sh	$25.58	+$58.1K	2,272
2019-01-22	Sage Therapeutics, Inc.Stock Options (Right to buy)A Award	Director	AAward	+20K sh	—	—	20,000
2018-02-28	ENTAENANTA PHARMACEUTICALS INC · Stock Option (right to buy)A Award	Director	AAward	+7,500 sh	—	—	7,500

Recent filings

Accepted (ET)
Jun 54
Golumbeski George0001628280-26-041268
SEC(opens sec.gov)
Jun 24
Golumbeski George0001193125-26-254126
SEC(opens sec.gov)
Dec 54
Golumbeski George0001193125-25-308770
SEC(opens sec.gov)
Nov 104
Golumbeski George0001586660-25-000003
SEC(opens sec.gov)
Jul 314
Golumbeski George0000950170-25-100666
SEC(opens sec.gov)
Jul 164
Golumbeski George0000950170-25-096275
SEC(opens sec.gov)
Jun 134
Golumbeski George0000950170-25-085818
SEC(opens sec.gov)
Jun 134
Golumbeski George0001562180-25-004793
SEC(opens sec.gov)
Jan 64
Golumbeski George0001562180-25-000164
SEC(opens sec.gov)
Jul 314
Golumbeski George0000950170-24-088534
SEC(opens sec.gov)
Jun 214
Golumbeski George0000950170-24-076393
SEC(opens sec.gov)
Jun 114
Golumbeski George0001562180-24-004952
SEC(opens sec.gov)
Jan 44
Golumbeski George0001562180-24-000224
SEC(opens sec.gov)
Jun 164
Golumbeski George0001562180-23-005260
SEC(opens sec.gov)
May 314
Golumbeski George0000950170-23-025375
SEC(opens sec.gov)
Jan 54
Golumbeski George0001562180-23-000235
SEC(opens sec.gov)

Companies

Address

C/O ACUMEN PHARMACEUTICALS, INC. 1210-1220 WASHINGTON STREET, SUITE 210

NEWTON, MA, 02465